BCL2L1 and breast cancer: Finally, we demonstrate that, in MDA-MB-231, a Bcl-xL-dependent breast cancer cell model, endogenous Bcl-xL can exploit this mechanism to suppress IP3R activity and to counteract Ca2+-driven apoptosis.